As a company focused on human milk-based nutrition for premature infants it is important to us that our products are safe.
Donor breast milk often contains Bacillus cereus (Bc), a bacteria widely found throughout nature but is especially dangerous to at-risk infants because it can activate Necrotizing Enterocolitis (NEC), a devastating intestinal disease that affects premature or very low birth weight infants.
The development and validation of Gentle-UHT, our proprietary technology, took place over three years and we’re excited to announce that it successfully inactivates Bacillus Cereus from all the milk we will process.
“Bc is often found in donor milk. Being able to inactivate this bacteria was a critical part of these processing runs,” shared Glenn Snow, CEO and Co-Founder of LactaLogics. “The good news is we have clear data showing that Gentle-UHT offers superior retention of proteins, immune factors, and HMOs while inactivating deadly bacteria, viruses, molds, and spores like Bc.”
We completed five different R&D and commercialization-scale runs, each with its own donor screening, donor qualification, milk screening, milk pooling, and milk testing.
“This is a huge victory for innovation in neonatal nutrition,” continued Snow. “Gentle-UHT successfully addresses Bc by inactivating it, life-changing news for our smallest and most vulnerable patients. The future of human milk-based products is very bright.”
Want more information? Read more about our first, second, and third commercialization-scale processing runs.
